| Besins Healthcare | |
| Type: | Privately held company |
| Industry: | Pharmaceutical |
| Founded: | 1885 |
| Founder: | Abel Besins and Joseph Lebeau |
| Hq Location: | Monaco |
| Area Served: | Worldwide |
| Key People: | Nicolas Besins and Alexandre Besins (Chief Executive Officers) |
| Products: | Pharmaceutical products • Hormone replacement therapies |
| Revenue: | €500 million |
| Revenue Year: | 2023 |
| Num Employees: | 1,500+ |
| Website: | https://besins-healthcare.com/ |
Besins Healthcare is a privately held, fifth-generation family-owned multinational pharmaceutical company headquartered in Monaco. Founded in 1885 in Paris, Besins Healthcare focuses on transdermal delivery technology treatments and has products available in 100 countries.
The company specializes in manufacturing and developing drugs for the treatment of gynecological, fertility, and obstetrical conditions as well as androgen deficiencies.[1] Besins Healthcare has three subsidiaries: BHR Pharma, LLC, Ascend Therapeutics and Pure Matters.
Ascend Therapeutics is involved in the research and development of transdermal drugs that are applied to the skin as a gel to treat chronic conditions such as severe breast pain for pre-menopausal women, and low testosterone levels for older men.[1]
Besins Healthcare was founded in 1885 by Abel Besins and Joseph Lebeau.[2]
Throughout the 1980s and 1990s, the company expanded its portfolio to include treatments for a variety of hormonal conditions.
In November 2022, Oregon Attorney General Ellen Rosenblum sued AbbVie, Abbott Laboratories, Unimed Pharmaceuticals. The lawsuit alleges that the four pharmaceutical companies, which held the exclusive patent for brand-name AndroGel, filed baseless lawsuits to monopolize the market and prevent competitors from entering, which resulted in much higher prices.[3]
The FTC filed a complaint in federal district court in September 2014 charging that AbbVie Inc. and its partner Besins Healthcare Inc. illegally blocked American consumers’ access to lower-cost alternatives to Androgel by filing baseless patent infringement lawsuits against potential generic competitors. In a June 2018 decision, the U.S. District Court for the Eastern District of Pennsylvania ruled that sham litigation was used to create a monopoly.[4]